AG Bartneck

Bartneck Lab aims to generate and explore smart nucleic acid therapeutics

Where medicine meets chemistry!

Nucleic acids have been recognized as a potential drug during the COVID19 pandemic. Systemic administration of drugs with nucleic acid as active compound inevitably result in side effects caused by off-target effects. Our groups studies novel carrier types that enable an activation of therapeutic nucleic acids by external stimuli. To realize this, we work together closely with the DWI – Leibniz-Institut for Interaktive Materialials e.V.

Learn more about Bartneck lab: